LAMEA Antibiotics Market Size, Growth & Trends 2020-2026

LAMEA Antibiotics Market By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors), By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others), By Country, Industry Analysis and Forecast, 2020 - 2026

Published Date: February-2021 | Number of Pages: 97 | Format: PDF | Report ID: KBV-14296

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Antibiotics Market, by Action Mechanism
1.4.2 LAMEA Antibiotics Market, by Drug Class
1.4.3 LAMEA Antibiotics Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players

Chapter 4. LAMEA Antibiotics Market by Action Mechanism
4.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
4.2 LAMEA Protein Synthesis Inhibitors Market by Country
4.3 LAMEA DNA Synthesis Inhibitors Market by Country
4.4 LAMEA RNA Synthesis Inhibitors Market by Country
4.5 LAMEA Others Market by Country

Chapter 5. LAMEA Antibiotics Market by Drug Class
5.1 LAMEA Cephalosporin Market by Country
5.2 LAMEA Penicillin Market by Country
5.3 LAMEA Fluoroquinolone Market by Country
5.4 LAMEA Macrolides Market by Country
5.5 LAMEA Carbapenem Market by Country
5.6 LAMEA Aminoglycosides Market by Country
5.7 LAMEA Sulfonamides Market by Country
5.8 LAMEA Others Market by Country

Chapter 6. LAMEA Antibiotics Market by Country
6.1 Brazil Antibiotics Market
6.1.1 Brazil Antibiotics Market by Action Mechanism
6.1.2 Brazil Antibiotics Market by Drug Class
6.2 Argentina Antibiotics Market
6.2.1 Argentina Antibiotics Market by Action Mechanism
6.2.2 Argentina Antibiotics Market by Drug Class
6.3 UAE Antibiotics Market
6.3.1 UAE Antibiotics Market by Action Mechanism
6.3.2 UAE Antibiotics Market by Drug Class
6.4 Saudi Arabia Antibiotics Market
6.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
6.4.2 Saudi Arabia Antibiotics Market by Drug Class
6.5 South Africa Antibiotics Market
6.5.1 South Africa Antibiotics Market by Action Mechanism
6.5.2 South Africa Antibiotics Market by Drug Class
6.6 Nigeria Antibiotics Market
6.6.1 Nigeria Antibiotics Market by Action Mechanism
6.6.2 Nigeria Antibiotics Market by Drug Class
6.7 Rest of LAMEA Antibiotics Market
6.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
6.7.2 Rest of LAMEA Antibiotics Market by Drug Class

Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities